Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE launches $250 million fund for device investments

This article was originally published in The Gray Sheet

Executive Summary

GE Healthcare plans to invest $250 million in "high potential" health care technology companies through its GE Healthymagination Fund, launched Oct. 21. A component of the firm's recently unveiled Healthymagination initiative, a global commitment "to deliver better health care to more people at lower cost," the equity investment fund will target three broad areas for investment: diagnostics, health care information technology and life sciences, according to the company (1"The Gray Sheet" May 11, 2009)

You may also be interested in...

GE’s ‘Healthymagination’ Campaign Reflects New Focus On Low Cost Products

GE will shift more of its health care R&D spending toward lower-priced medical products over the next six years under an initiative announced May 7

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts